Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis
Authors:
- 3 February 2025
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (6)
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2024
- Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohortJournal of the European Academy of Dermatology and Venereology, 2023
- Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJournal of the European Academy of Dermatology and Venereology, 2023
- Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of ObservationAmerican Journal of Clinical Dermatology, 2023
- National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic DermatitisJournal of Clinical Medicine, 2022
- Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristicsJournal of the European Academy of Dermatology and Venereology, 2022
- Nomenclature and clinical phenotypes of atopic dermatitisTherapeutic Advances in Chronic Disease, 2021
- Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 PatientsJournal of Clinical Medicine, 2020
- Atopic dermatitis endotypes and implications for targeted therapeuticsJournal of Allergy and Clinical Immunology, 2019
- Atopic Dermatitis in Adults: A Diagnostic ChallengeJournal of Investigational Allergology and Clinical Immunology, 2017